Core Insights - Vistagen is a late clinical-stage biopharmaceutical company focused on developing intranasal product candidates known as pherines [1] - The company will present data on its investigational pherine nasal spray, PH80, at The Menopause Society 2025 Annual Meeting [1] - PH80 is characterized as a novel, non-systemic, and non-hormonal treatment option [1] Company Overview - Vistagen specializes in neuroscience and aims to pioneer new therapeutic approaches through nose-to-brain neurocircuitry [1] - The company is publicly traded on Nasdaq under the ticker VTGN [1] Upcoming Events - The presentation of PH80 data is scheduled for October 23, 2025, in Orlando, Florida [1]